scholarly journals Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan

2021 ◽  
Author(s):  
Chi‐Yi Chen ◽  
Chung‐Feng Huang ◽  
Pin‐Nan Cheng ◽  
Kuo‐Chih Tseng ◽  
Ching‐Chu Lo ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Failure ◽  
Chronic Hepatitis C ◽  
Real World ◽  
Direct Acting Antivirals ◽  
Factors Associated ◽  
Direct Acting

scholarly journals Detection of drug resistance mutations of hepatitis C virus in patients with failure of the treatment with direct acting antivirals

2021 ◽  
Vol 98 (1) ◽  
pp. 18-27
Author(s):  
D. E. Valutite ◽  
A. V. Semenov ◽  
Yu. V. Ostankova ◽  
K. V. Kozlov ◽  
A. G. Borisov ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Failure ◽  
Chronic Hepatitis C ◽  
Direct Acting Antivirals ◽  
Resistance Mutations ◽  
Drug Resistance Mutations ◽  
Direct Acting

Background. The development of direct acting antivirals (DAAs) has spurred a revolution in treatment of patients with chronic hepatitis C. However, there are cases showing no response to treatment. In 5% of cases, the viral breakthrough is most likely caused by DAA resistance mutations in the hepatitis C virus genome.The purpose of the study is to detect drug resistance mutations of hepatitis C virus in patients with DAA treatment failure.Materials and methods. The study was performed on plasma samples from 3 patients diagnosed with chronic hepatitis C virus infection and demonstrating DAA virological treatment failure. All isolates had genotype 1b. Drug resistance mutations were detected by using direct sequencing of NS3, NS5A, and NS5B genome regions. The detection technique was developed at the Pasteur Research Institute of Epidemiology and Microbiology.Results. Drug resistance mutations were detected in all cases. By using the Geno2pheno [hcv] 0.92 tool, nucleotide substitutions were detected in different viral genome regions and presumably caused resistance or decreased sensitivity to antivirals both present and absent in the sofosbuvir + daclatasvir combination therapy. Antiviral treatment failure in patients with chronic hepatitis C is caused by drug resistance mutations.Conclusions. The developed technique is efficient for detection of drug resistance mutations in NS3, NS5A, and NS5B regions in cases of virological failure of DAA treatment.

scholarly journals Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C

PLoS ONE ◽  
2020 ◽  
Vol 15 (3) ◽  
pp. e0229994
Author(s):  
Sheng Feng Lin ◽  
Shui-Yi Tung ◽  
Kuo-Liang Wei ◽  
Chien-Hung Chen ◽  
Tsung-Hui Hu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Clinical Utility ◽  
Core Antigen ◽  
Direct Acting Antivirals ◽  
Virus Core ◽  
Antigen Assay ◽  
Direct Acting

Su1453 Real World Experience With Interferon-Free Direct Acting Antivirals in the Treatment of Patients With Chronic Hepatitis C

2016 ◽  
Vol 150 (4) ◽  
pp. S1104
Author(s):  
Baraa M. Abduljawad ◽  
Jenny M. Hatch ◽  
Keisa Lynch ◽  
Kerin Stevens ◽  
I Ray Thomason ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Real World ◽  
Direct Acting Antivirals ◽  
Direct Acting

scholarly journals Korszakváltás a krónikus C-vírus hepatitis terápiájában – új direkt ható antivirális szerek

2015 ◽  
Vol 156 (21) ◽  
pp. 841-848
Author(s):  
Gábor Horváth ◽  
Tünde Halász ◽  
Mihály Makara ◽  
Béla Hunyady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Viral Response ◽  
Virus Hepatitis ◽  
Direct Acting Antivirals ◽  
Screening Programs ◽  
Viral Response ◽  
Direct Acting

Chronic hepatitis C, without treatment, can cause liver cirrhosis, liver failure and liver cancer. The availability of new oral direct acting antivirals, such as the protease inhibitors simeprevir, asunaprevir and paritaprevir, the NS5A inhibitors daclatasvir, ledipasvir, and ombitasvir, the polymerase inhibitors Sofosbuvir and dasabuvir have resulted an enormous progress in the treatment of chronic hepatitis C, leading to >90% sustained viral response rates. Even the hard-to-treat or previously treatment ineligible patients can be cured with the combination of these drugs. Furthermore the treatment duration is much shorter, and the side effects are minimal. Today, treatment of all hepatitis C virus infected patients is recommended, and the best choices are the interferon-free options. Eradication of hepatitis C virus has become realistic, however, appropriate screening programs are mandatory to achieve this goal. Orv. Hetil., 2015, 156(21), 841–848.

scholarly journals Predictors of Direct-Acting Antivirals Failure in Patients with Chronic Hepatitis C Virus in Ivory Coast: About 5 Cases

2019 ◽  
Vol 09 (10) ◽  
pp. 193-201
Author(s):  
Dimitri Hatrydt Kouamé ◽  
Stanislas Adjéka Doffou ◽  
Henriette Kissi Anzouan-Kacou ◽  
Yannick Mfupa Tchana ◽  
Aboubakar Demba Bangoura ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Ivory Coast ◽  
Direct Acting Antivirals ◽  
Chronic Hepatitis C Virus ◽  
Direct Acting

scholarly journals Association Between Vitamin D Levels and Treatment Response to Direct-Acting Antivirals in Chronic Hepatitis C: A Real-World Study

2018 ◽  
Vol 11 (4) ◽  
pp. 309-316 ◽  
Author(s):  
Vijay Gayam ◽  
Amrendra Kumar Mandal ◽  
Mazin ◽  
Khalid ◽  
Osama Mukhtar ◽  
...  
Keyword(s):  
Vitamin D ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Treatment Response ◽  
Chronic Hepatitis C ◽  
Real World ◽  
Direct Acting Antivirals ◽  
Vitamin D Levels ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document